Adakitug by Bristol-Myers Squibb for Hormone-Sensitive Prostate Cancer: Likelihood of Approval

Adakitug is under clinical development by Bristol-Myers Squibb and currently in Phase II for Hormone-Sensitive Prostate Cancer.

Foresite Capital Closes $900M Fund Targeting Precision Medicine & Innovation

What You Should Know: – Foresite Capital, a San Francisco, CA-based healthcare and life sciences investment firm, announced today the successful closing of its sixth

June 12, 2024

Inovalon and MEDITECH Alliance Partner to Streamline Revenue Cycle Management

What You Should Know: – Inovalon, an innovator in cloud-based healthcare data solutions, announced a strategic partnership with the MEDITECH Alliance. – The strategic collaboration

June 28, 2024

U.S. drug overdose deaths on pace to fall below 100,000 this year

U.S. drug overdose deaths are plummeting, putting the country on pace for its first year with fewer than 100,000 overdose deaths since 2020 — a

November 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.